Autonomic Function in COPD and Risk for Atrial Fibrillation
Characterization of Autonomic Function in Patients With Chronic Obstructive Pulmonary Disease - Potential Relevance for Increased Risk of Atrial Fibrillation
1 other identifier
observational
50
1 country
1
Brief Summary
In the presented study, autonomic function as well as risk for atrial fibrillation will be assessed to characterize the relation between risk of atrial fibrillation and autonomic function.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2019
CompletedFirst Submitted
Initial submission to the registry
March 11, 2019
CompletedFirst Posted
Study publicly available on registry
March 12, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2019
CompletedNovember 8, 2019
November 1, 2019
6 months
March 11, 2019
November 7, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
total atrial conduction time
total atrial conduction time via tissue Doppler imaging (PA-TDI interval)
Baseline
Secondary Outcomes (7)
Heart rate variability
Baseline
Baroreflex sensitivity
Baseline
Chemoreflex sensitivity
Baseline
Deep breathing test
Baseline
Ewing test
Baseline
- +2 more secondary outcomes
Study Arms (2)
AECOPD
acute exacerbation of COPD
stable COPD
Interventions
Measurement of lung function, electrocardiography, echocardiography and autonomic function
Eligibility Criteria
Patients with chronic obstructive pulmonary disease, exacerbated or stable
You may qualify if:
- patients with chronic obstructive pulmonary disease, exacerbated or stable between the age of 40-80 years with sinus rhythm who gave informed written consent
You may not qualify if:
- Inability to give written consent, acute myocardial infarction with ST-segment elevations in last 30 days, severe acute or chronic renal dysfunction, severe heart failure, atrial fibrillation, severe valve disease, severe hypotension, active malignant disease, active rheumatic disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Düsseldorf, Division of Cardiology, Pulmonary Disease and Vascular Medicine
Düsseldorf, 40225, Germany
Biospecimen
Collection of 20 ml of peripheral blood Clinical routine such as NTproBNP, renal function, thyroid function, blood count
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principle Investigator
Study Record Dates
First Submitted
March 11, 2019
First Posted
March 12, 2019
Study Start
March 1, 2019
Primary Completion
August 31, 2019
Study Completion
August 31, 2019
Last Updated
November 8, 2019
Record last verified: 2019-11
Data Sharing
- IPD Sharing
- Will not share